Allarity Therapeutics Board Changes
Ticker: ALLR · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1860657
Sentiment: neutral
Topics: board-change, director-appointment, director-departure
TL;DR
Allarity Therapeutics swapped a director and added a new board member with committee roles.
AI Summary
Allarity Therapeutics, Inc. announced on February 28, 2024, a change in its board of directors. Specifically, the company reported the departure of Director James E. Robinson III and the election of Dr. Torbjörn Bjerke as a new Class II director. The filing also noted the appointment of Dr. Bjerke as a member of the Audit Committee and Compensation Committee.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty regarding strategic direction and operational oversight.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- James E. Robinson III (person) — Departing Director
- Dr. Torbjörn Bjerke (person) — Newly Elected Director
- February 28, 2024 (date) — Date of earliest event reported
FAQ
Who departed from the Allarity Therapeutics board of directors?
James E. Robinson III departed from the board of directors.
Who was elected as a new director to Allarity Therapeutics' board?
Dr. Torbjörn Bjerke was elected as a new Class II director.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported was on February 28, 2024.
Which committees was Dr. Torbjörn Bjerke appointed to?
Dr. Torbjörn Bjerke was appointed to the Audit Committee and the Compensation Committee.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The principal executive office is located at 24 School Street, 2nd Floor, Boston, MA 02108.
Filing Stats: 391 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-03-04 16:05:59
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0201126-8k_allarity.htm (8-K) — 30KB
- 0001213900-24-019540.txt ( ) — 200KB
- allr-20240228.xsd (EX-101.SCH) — 3KB
- allr-20240228_lab.xml (EX-101.LAB) — 33KB
- allr-20240228_pre.xml (EX-101.PRE) — 22KB
- ea0201126-8k_allarity_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: March 4, 2024 By: /s/ Thomas Jensen Thomas Jensen Chief Executive Officer 2